3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome
MONDO:0013875Any 3-methylglutaconic aciduria in which the cause of the disease is a mutation in the SERAC1 gene.
Also known as: 3-methylglutaconic aciduria caused by mutation in SERAC1, 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome, 3-methylglutaconic aciduria with deafness-encephalopathy-Leigh-like syndrome, MEGDEL, MEGDEL syndrome, MGCA6, SERAC1 3-methylglutaconic aciduria, 3-MGCA type IV (formerly)
13 clinical trials for this condition and its sub-types, 0 tagged with 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug shows promise for rare energy disorder
Disease control CompletedThis study tested a new drug called OMT-28 in 28 people with primary mitochondrial disease, a condition that affects how cells produce energy. Participants took the drug once daily for 6 months, and researchers measured safety, blood markers of inflammation, and symptoms like fat…
Phase 2 • Sponsor: Omeicos Therapeutics GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Long-Term safety of mitochondrial drug confirmed in 101 patients
Disease control CompletedThis study looked at the safety of vatiquinone in 101 people with inherited mitochondrial disease who had already taken the drug in a previous study or treatment plan. The goal was to track any side effects until the drug became commercially available or the program ended. Partic…
Phase 3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC